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Abstract
Background: Lack of health insurance coverage is associated with poor access and receipt of cancer care and survival in the
United States. Disruptions in coverage are common among low-income populations, but little is known about associations of
disruptions with cancer care, including prevention, screening, and treatment, as well as outcomes of stage at diagnosis and
survival. Methods: We conducted a systematic review of studies of health insurance coverage disruptions and cancer care
and outcomes published between 1980 and 2019. We used the PubMed, EMBASE, Scopus, and CINAHL databases and
identified 29 observational studies. Study characteristics and key findings were abstracted and synthesized qualitatively.
Results: Studies evaluated associations between coverage disruptions and prevention or screening (31.0%), treatment (13.8%),
end-of-life care (10.3%), stage at diagnosis (44.8%), and survival (20.7%). Coverage disruptions ranged from 4.3% to 32.8% of
patients age-eligible for breast, cervical, or colorectal cancer screening. Between 22.1% and 59.5% of patients with Medicaid
gained coverage only at or after cancer diagnosis. Coverage disruptions were consistently statistically significantly associated
with lower receipt of prevention, screening, and treatment. Among patients with cancer, those with Medicaid disruptions
were statistically significantly more likely to have advanced stage (odds ratios ¼ 1.2-3.8) and worse survival (hazard ratios ¼
1.28-2.43) than patients without disruptions. Conclusions: Health insurance coverage disruptions are common and adversely
associated with receipt of cancer care and survival. Improved data infrastructure and quasi-experimental study designs will
be important for evaluating the associations of federal and state policies on coverage disruptions and care and outcomes.

Lack of health insurance coverage is one of the strongest predictors of poor cancer outcomes in the United States (1–4). The uninsured are less likely to receive evidence-based care throughout
the cancer control continuum, including prevention and screening, diagnosis, treatment (ie, surgery, radiation therapy, and systemic therapies) and symptom management, survivorship, and
end-of-life care than their counterparts with health insurance
coverage (2,5). The uninsured are also more likely to have later
stage of disease at diagnosis (6,7) and poorer survival (4,7).
Because health insurance coverage can reduce health disparities
in populations defined by race or ethnicity, poverty, and geography (2,8–13), expanding public and private health insurance coverage options has been the focus of many policy efforts.

Following the implementation of the Affordable Care Act
(ACA), there were historic increases in the number of workingage Americans with health insurance coverage (14). Even so,
some adults experience insurance coverage losses and/or gains
within a single year (15,16). Coverage disruptions and health insurance coverage churn are especially common among the poor
and those with Medicaid coverage (17). Research conducted in
pediatric populations consistently shows that health insurance
coverage disruptions are associated with reduced access to care
(18). In the few studies of coverage disruptions conducted in
adults, even a single loss of coverage of at least 1 month is associated with worse access to care (19), delaying or forgoing care
(20), more emergency department use (15,21,22), and declines in
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Methods
Literature Review

REVIEW

Because a standard definition of coverage disruptions does not
exist, we defined health insurance coverage disruptions as gaps
in coverage, losses or gains of public or private coverage, timing
of coverage (eg, pre-, peri-, or postcancer diagnosis), or transitions between types of coverage (eg, public and private) or specific health insurance plans. We used the PubMed, EMBASE,
Scopus, and CINAHL databases to identify studies assessing
health insurance coverage disruptions and cancer care or outcomes in the United States and published in English between
January 1, 1980, and July 31, 2019. We started the literature
search in 1980 and ended with the most recent year to ensure
we identified as many relevant studies as possible. In the
PubMed database, our search strategy combined Medical
Subject Heading and title and abstract terms for neoplasms,
health insurance coverage, and health insurance enrollment
(see Supplemental Methods, available online). This search strategy was replicated in the EMBASE, Scopus, and CINAHL databases, and the combined searches yielded 1523 unique articles.
A single reviewer (J.Z.) assessed the abstracts of these articles
for eligibility. Included studies were required to quantitatively
assess insurance coverage at more than 1 time point to allow
measurement of coverage disruptions (a period with insurance
coverage and a period either without coverage or with a change
in coverage) and examine the association between coverage disruption and cancer-related care (ie, prevention, screening,
follow-up of abnormal findings, treatment, survivorship, or
end-of-life care) or outcomes (ie, stage of disease at diagnosis,
survival). We excluded studies conducted outside the United
States or whose only source of health insurance coverage information was from cancer registry data, because registries only
report coverage at a single time point consolidated after cancer
diagnosis. We also excluded editorials, commentaries, and review articles. Questions about article eligibility were resolved by
consensus. Following abstract review, 66 full articles were
reviewed, and of these, 24 met the inclusion criteria. Reference
lists of included articles were hand-searched, and an additional
5 articles were identified for a total of 29 articles (27–55). This
systematic review was conducted in accordance with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines (http://prisma-statement.org/). Supplemental Table 1
(available online) describes the search terms used in the

literature review, and Supplemental Figure 1 (available online)
illustrates the search process.

Data Abstraction
Data were abstracted on study characteristics, including year of
publication, data source(s), geographic setting (national, multiple states/cities, single state), and study design (cross-sectional,
cohort, intervention). Component(s) of the cancer control continuum (prevention, screening, treatment, survivorship/survival, and end-of-life care) and outcome measures (receipt of
care, stage at diagnosis, survival and/or mortality, spending)
were also recorded. Although earlier stage of disease at diagnosis can reflect receipt of regular screening for breast, cervical,
and colorectal cancers, screening tests are not recommended
for other cancers. Additionally, early evaluation of signs and
symptoms can play an important role in diagnosis. For these
reasons, we abstracted and reported findings for stage at diagnosis separately from cancer screening.
Patient characteristics included sample size, age range or
age distribution, and cancer diagnosis if the study was conducted in patients with cancer. The source of health insurance
coverage measures included registry, self-report, and Medicaid
enrollment. The type of insurance coverage disruption was abstracted as reported in underlying articles and later classified as
a coverage gap, the measured duration of coverage or coverage
gap, and timing of coverage (eg, pre-, peri-, or postcancer diagnosis). Similarly, data on comparison groups were classified by
insurance type, continuously insured or previously insured, duration of coverage (eg, <12 months vs 12 months), and timing
of coverage. Key findings abstracted from each article noted the
prevalence and type of coverage disruption and the associations
between coverage disruption and care and/or outcomes. A single author (J.Z.) abstracted data from the included studies, and
another author (K.R.Y.) reviewed these data. Any inconsistencies were resolved by consensus. The heterogeneity of underlying study populations, coverage disruption measures, time
periods, and component of the cancer control continuum precluded a quantitative data synthesis. We performed a qualitative synthesis of study findings by outcome examined.

Results
Study, Patient, and Insurance Coverage Characteristics
Most studies were conducted and published before 2014, conducted in a single state, and used cancer registry data linked to
Medicaid enrollment data (Table 1). Studies were published after the passage of the ACA in 2010, but none evaluated the
effects of the ACA on coverage disruptions or on the association
of disruptions with care receipt or outcomes. Studies also used
survey data or Medicaid enrollment and claims data only without registry linkage. Outcomes from claims, such as screening
or treatment, are reported only during periods of continuous
coverage. Studies evaluated associations between coverage disruptions and prevention or screening (31.0%), stage of disease at
diagnosis (44.8%), treatment (13.8%), survivorship or survival
(20.7%), and end-of-life care (10.3%). A single study evaluated
health-care spending. Most were conducted in samples of at
least 1000 patients, and among studies that evaluated patients
after a cancer diagnosis, the most common types were breast,
cervical, colorectal, and lung.
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overall health (15). Transitions between health plans can also
disrupt access to usual source of care and provider networks.
However, to date, most research on the health effects of insurance coverage has measured and evaluated coverage at only a
single point in time (eg, at cancer diagnosis) (3,4,23–26), and
synthesis of research addressing the effects of disruptions in
insurance coverage on cancer care and outcomes across the
cancer control continuum is needed. Understanding the associations of coverage disruptions with care is especially relevant given the rapidly changing health insurance landscape
in the United States. In this study, we conducted a systematic
review of published peer-reviewed research to assess the
associations of health insurance coverage disruptions with
care and outcomes, including cancer prevention, screening,
and stage of disease at diagnosis, treatment, survival, and
end-of-life care.
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Characteristics

Characteristics
Duration of coverage
Timing of coverage (eg, pre- or
postdiagnosis)
Comparison groupa
Continuously insured or continuously
uninsured
Continuously insured and continuously
uninsured
Prediagnosis coverage
Duration of coverage
Other

10 (34.5)
5 (17.2)
7 (24.1)
7 (24.1)
4 (13.8)
2 (6.9)
23 (79.3)
19 (65.5)
4 (13.8)
6 (20.7)
4 (13.8)
25 (86.2)
1 (3.4)
8 (27.6)
13 (44.8)
4 (13.8)
6 (20.7)
3 (10.3)
15 (51.7)
13 (44.8)
7 (24.1)
1 (3.1)

3 (10.3)
11 (37.9)
15 (51.7)
13 (44.8)
21 (72.4)
25 (82.8)
8 (27.6)
6 (20.7)
6 (20.7)
6 (20.7)
4 (13.8)
3 (10.3)
2 (6.9)
9 (31.0)

22 (75.9)
7 (24.1)
1 (3.4)
6 (20.7)
21 (72.4)
1 (3.4)
8 (27.6)
2 (6.9)
(continued)

No. of studies (%)
(N ¼ 29)
12 (41.4)
18 (62.1)

11 (37.9)
5 (17.2)
9 (31.0)
4 (13.8)
2 (6.9)

a

Categories are not mutually exclusive, and studies were included in multiple

categories. AYA ¼ Adolescents and young adult.

Nearly three-quarters of studies used Medicaid enrollment
and claims data as the source of health insurance coverage;
self-report was less common. There was substantial heterogeneity across studies in the types of coverage disruptions evaluated. Studies evaluated coverage gaps (27.6%), timing of
coverage, either pre- or postdiagnosis (62.1%), as well as the duration of coverage (41.4%) or coverage gap (6.9%). Many studies
evaluated multiple types of disruptions. The type of coverage
disruption varied by data source and outcome measured. For
example, most studies evaluating stage of disease at diagnosis
used measures about the timing of coverage pre-, peri-, and/or
postdiagnosis. The number of months used to measure the timing of coverage varied widely.
All studies included a comparison group, although comparison groups varied, and included the continuously insured,
without Medicaid coverage (both uninsured and insured), insured before diagnosis, and a combination of continuously insured and continuously uninsured. Although some studies
included populations with all types of coverage, including private coverage, none of the studies evaluated coverage disruptions exclusively among those with private coverage or
transitions between different private insurance plans.
Heterogeneity of geographic region, patient population, measures, and outcomes in the underlying studies precluded the
measurement of trends over time.

Cancer Prevention and Screening
For the studies evaluating cancer prevention and screening,
details of study populations, settings, measures of coverage disruptions and outcomes, comparison groups, and key findings
are listed in Table 2. One study evaluated associations between
coverage disruptions and HPV vaccination in adolescent girls
(39), and 8 studies examined associations between disruptions
and cancer screening in age-eligible adults (27–32,37,38).
Prevalence of coverage disruptions ranged from 4.3% to 32.8% in
samples of adults without a cancer history and age-eligible for
cancer screening in studies that reported this information
(27,30). Coverage disruptions were statistically significantly associated with less frequent receipt of prevention or screening in
7 of 9 studies; associations were null in the remaining 2 studies.
Coverage disruptions were statistically significantly associated
with less use of mammography (27–29,32,37) and Pap testing
(27–29) compared with continuously insured women or women
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Study characteristics
Publication year
2000-2004
2005-2009
2010-2014
2015-2019
Geographic setting
National
Multiple cities and/or states
Single state
Data source
Cancer registry - Medicaid enrollment, 6
claims
Medicaid enrollment, claims
Survey
Study design
Cross-sectional
Cohort
Component of cancer control continuuma
Prevention
Screening
Stage of diagnosis
Treatment
Survivorship/survival
End-of-life care
Study outcome(s)a
Access to care or receipt of care
Stage of disease at diagnosis
Survival or mortality
Spending
Patient characteristics
No. of patients
<999
1000-9999
10 000þ
Age groupa
<18
18-39
40-64
Cancer site(s)a
Breast
Cervical
Colorectal
Lung
Other cancer sites
Multiple cancer types (eg, gynecologic,
AYA)
All cancer sites
Without cancer
Insurance coverage
Coverage disruption evaluated
Medicaid only
Multiple types of coverage
Source of coverage measure
Registry
Self-report
Enrollment and claims
Other
Coverage disruption measure(s)a
Coverage gap
Duration of coverage gap

No. of studies (%)
(N ¼ 29)

Table 1. (continued)

REVIEW

Table 1. Study, patient, and insurance coverage characteristics

223 128 adults
aged 18-64
y

11 755 women
aged 21-64
y

1512 women
aged 18 y

333 adults
aged 40-74
y

92 809 adults
aged 18 y

Bednarek and
Schone, 2003 (28)

Broyles et al., 2002
(29)

Freund et al., 2019
(30)

Jerant et al., 2013 (31)

Sample size,
No.

Self-reported insurance instability in past 12 mo defined as uninsured, losing
coverage, or changing insurance vs stable insurance status (insured,
uninsured)

Minority race/ethnicity or low SES
participants recruited across
4 sites in 3 states: Chinese
Americans in Boston, MA;
Hispanic in Columbus, OH;
Appalachian populations in
OH’s Appalachian region; and
African American and Black
populations in Philadelphia, PA.
Patients recruited from community-based organizations, faithbased organizations, public
housing, screening events,
health fairs, and from existing
research studies. Years of data
collection not stated
National; MEPS, 2000-2008; 2-y
panels
Self-reported insurance loss
during 2-y follow-up period vs no private and/or
public coverage change
(continuously insured

Self-reported temporarily
uninsured with coverage
gap previous year vs continuously insured

Self-reported short-term
uninsured (uninsured
<1 y) with coverage gap
<1 year vs currently insured (private and/or
public)
Self-reported duration of
private or public coverage, measured as 1-6 mo,
7-11 mo vs all 12 mo

Insurance coverage
measures

Oklahoma’s BRFSS, 1993

National; MEPS, 1996

National; BRFSS, 1997-1998

Setting, data source, and year

Percentage short-term insured 1-6 and 7-11 mo not
reported
Compared with continuously insured for 12 mo, insured
for 1-6 mo less likely to have Pap smears (79.9% vs 70.7%,
P < .05) or mammograms (66.7% vs 53.6%, P < .05)
Compared with insured 7-12 mo, insured 1-6 mo were
less likely to have Pap smears (81.8% vs 70.7%, P < .05)
or mammograms (67.0% vs 53.6%, P < .05).
Continuously insured and insured 7-12 mo did not statistically significant differ
Percentage temporarily uninsured in previous year not
reported
Use of mammograms and Pap smears similar in temporarily uninsured and continuously insured (OR ¼ 0.8
and OR ¼ 0.9, respectively; both P > .05)
32.8% reported insurance instability
No statistically significant differences in BC (72.6% vs
80.6%, P ¼ .23), cervical cancer (67.2% vs 73.4%, P ¼ .48),
and CRC (61.4% vs 70.1%, P ¼ .19) screening between
adults with insurance coverage instability compared
with those with stable coverage
Self-reported use of mammography and Pap test
2 y among eligible
women

Self-reported use of CRC
screening (fecal occult
blood testing 2 y and/or
endoscopy 5 y), Pap test
3 y, and mammography

(continued)

3193 adults lost insurance. Those with insurance loss
less likely to receive Pap (OR ¼ 0.6, 95% CI ¼ 0.5 to 0.8)
and mammography (OR ¼ 0.6, 95% CI ¼ 0.4 to 0.8)
than those without insurance change. Also less likely
to receive CRC screenings, but association not statistically significant (OR ¼ 0.7, 95% CI ¼ 0.4 to 1.0)

4.3 % short-term uninsured
Compared with currently insured, short-term uninsured
were less likely to receive mammography (78.7% vs
89.0%, P < .05) or Pap test (89.5% vs 93.7%, P < .05)
No differences observed for receipt of CRC screenings

Self-reported Pap test 3 y,
mammography 2 y, fecal occult blood test 2 y,
and sigmoidoscopy 5 y
among eligible adults

Self-reported use of mammography (in the past
2 y) and Pap test screening (in the past 3 y)
among eligible women
Self-reported use of screening and date of last test.
Up to date for BC, cervical
cancer, or CRC screening
status calculated per
USPSTF

Key findings

Outcome measures
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Ayanian et al., 2000
(27)

Reference

REVIEW

Table 2. Health insurance coverage disruptions and cancer screeninga
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2036 adults
aged 60-64
y in 1996;
No. of
women not
stated

10 831 adults
who turned
50 y during
2010-2013

237 015 girls
aged 9-17 y

McWilliams et al.,
2003 (37)

O’Leary et al., 2019
(38)

Staras et al., 2010
(39)

Florida Medicaid enrollment and
claims, June 2006 to Dec 2008

Oregon Medicaid claims data,
2010-2014

National; Health and Retirement
Study, 1994, 1996

Ohio Medicaid claims and enrollment files, 1992-1999

Setting, data source, and year

Coverage duration measured as no. of months
enrolled in Medicaid
(1–31)

CRC screening with colonoscopy, sigmoidoscopy,
or stool testing from
claims within 12 mo of
age 50 y
At least 1 HPV vaccine
claim

Self-reported mammography 2 y

2 y among eligible
adults
Receipt of annual and regular annual screening
mammography from
claims

and continuously
uninsured)
Duration of coverage ¼
length of enrollment in
Medicaid (12, 13-24, 2536 mo, etc [up to 8 y])

Self-reported coverage gap
measured as intermittently insured (insured in
either 1994 or 1996) vs
privately and/or publicly
insured in both 1994 and
1996 (continuously
insured)
New enrollment in
Medicaid at 50 y vs prior
enrollment before 50 y

Outcome measures

Insurance coverage
measures

Percentages by duration of months enrolled in Medicaid
not reported
Longer length of Medicaid enrollment positively associated with receipt of at least 1 HPV vaccination. HPV
vaccination rates were 3.5%, 12.8%, 19.0%, 22.2%, 28.4%
for girls enrolled in Medicaid for 1-7, 8-13, 14-19, 20-25,
26-31 mo, respectively

Percentage newly enrolled not reported
No differences in CRC screening newly enrolled in
Medicaid and prior enrollment (RR ¼ 1.0, 95% CI ¼ 0.8
to 1.3, P ¼ .87)

40.7% enrolled 12 mo, 17.6% enrolled 13-24 mo, 41.7%
enrolled >24 mo
Proportion of women receiving screening mammography increased statistically significantly each additional year of Medicaid enrollment (AOR ¼ 1.6, 95% CI
¼ 1.6 to 1.6)
Mean annual mammograms increased from 0.08 in
women with enrollment 12 mo to 0.26 in women
with enrollment 7 y
216 were intermittently insured
Compared with continuously insured, intermittently insured less likely to receive mammography (76.0% vs
57.7%, P < .05)

Key findings
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AOR ¼ adjusted odds ratio; BC ¼ breast cancer; BRFSS ¼ Behavioral Risk Factor Surveillance Survey; CI ¼ confidence interval; CRC ¼ colorectal cancer; MEPS ¼ Medical Expenditure Panel Survey; OR ¼ odds ratio; RR ¼ risk ratio; SES
¼ socioeconomic status; USPSTF ¼ United States Preventive Services Task Force.

a

140 592
women
aged 40-64
y

Sample size,
No.

Koroukian, 2004 (32)

Reference

Table 2. (continued)
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Stage of Disease at Diagnosis

REVIEW

Among the 13 studies that examined coverage disruptions and
stage of disease at diagnosis, details for study populations, settings, measures of coverage disruptions and outcomes, comparison groups, and key findings are listed in Table 3
(33,34,40,41,43–51). Each of these studies examined timing of
Medicaid enrollment in a single state, including California,
Michigan, New Jersey, North Carolina, Ohio, or Washington.
Coverage disruption was measured as Medicaid enrollment timing in relation to diagnosis or as continuity of Medicaid coverage. The number of months used to define timing of coverage or
coverage continuity varied widely. Information about insurance
coverage before Medicaid enrollment was not available, and
patients could have been previously enrolled in private health
insurance plans or uninsured.
Among newly diagnosed patients with Medicaid coverage,
between 22.1% and 59.5% enrolled in Medicaid at or after diagnosis in studies that reported this information. Coverage disruptions were associated with advanced stage in all 13 studies,
with odds ratios ranging from 1.2 to 3.8. In studies that evaluated the effects of coverage disruptions by cancer site, disruptions were statistically significantly associated with advanced
stage for breast, cervical, colorectal, thyroid, lung, melanoma,
non-Hodgkin and Hodgkin lymphomas, and ovarian cancers.
None of the studies explicitly compared the magnitude of
associations between coverage disruptions for those cancers
with effective screening tests (ie, breast, cervical, colorectal) and
those cancers without effective screening tests that are typically
diagnosed at a later stage of disease. One study linked cancer
registry, Medicaid enrollment, and the Breast and Cervical
Cancer Early Detection Program (BCCEDP) data to assess onetime and repeat BCCEDP use and stage at breast cancer diagnosis (34) (previously uninsured women diagnosed with cancer as
a result of screening through BCCEDP are automatically enrolled
in Medicaid). Compared with prediagnosis Medicaid enrollees,
one-time BCCEDP users were more likely to be diagnosed with
advanced-stage breast cancer, but there was no statistically significant association with stage for repeat BCCEDP users.

disruptions and outcomes, comparison groups, and key findings
are listed in Table 4. Studies were conducted in California,
Georgia, Michigan, North Carolina, New Jersey, and Ohio.
Among newly diagnosed patients with Medicaid coverage, between 22.1% and 59.5% enrolled in Medicaid at or after diagnosis. In 3 of 4 studies evaluating treatment, coverage disruptions
were associated with treatment delay (51) and lower likelihood
of receiving treatment (44,52). Treatment delay and lack of definitive surgery were reported for multiple cancer sites, including breast, colon, lung, and gastric cancers (44,51,52). Two
relatively small studies reported null findings for the association between coverage disruption and receipt of treatment
(52,53); however, they measured both coverage disruptions and
treatment with Medicaid claims after diagnosis, limiting interpretation of findings because treatment could not be measured
among those without Medicaid coverage.
All 7 studies reported that survival following diagnosis was
statistically significantly worse for patients who gained
Medicaid coverage at or after diagnosis. Worse survival was
reported for multiple cancer types, including, breast, cervical,
colon, lung, and gastric cancers, with odds ratios or hazard ratios ranging from 1.28 to 2.43 (40,42,51). Several studies
reported that disparities in survival for those with coverage
disruptions were mediated by differences in stage at diagnosis
(40,45).
Although studies did not explicitly compare the magnitude
of associations between coverage disruptions for cancers with
and without effective screening tests, 1 study of patients with
breast cancer reported better cancer-specific and overall survival among previously uninsured one-time and repeat BCCEDP
users compared with other Medicaid enrollees (34).

End-of-Life Care and Health-Care Spending
Two studies evaluated coverage disruptions and end-of-life care
(54,55) and 1 evaluated spending among Medicaid enrollees
who died of cancer. Details for each study are listed in Table 5
(36). Studies were conducted in California, New York, and Ohio.
Disruptions were associated with statistically significantly less
use of hospice before death among patients diagnosed with
stage IV lung cancer compared with those with continuous
Medicaid coverage in 2 states (54). Similarly, disruptions were
associated with statistically significantly less hospice use
among those diagnosed with any cancer as adolescent and
young adults (55). Both studies reported a dose-response association, with lower odds of hospice use among those with greater
coverage discontinuity between diagnosis and death (54,55).
Discontinuous Medicaid coverage was also associated with less
use of other types of care, including aggressive treatment, measured as chemotherapy within 14 days of death, emergency
room visit, hospitalization, or intensive care unit stay within
30 days of death (55). Longer Medicaid enrollment was associated with higher per-person, per-month medical care spending
among patient with any cancer indicated as the underlying
cause of death (36), although no age restriction on the date of
death was used and 61% were aged 65 years and older and ageeligible for Medicare coverage.

Cancer Treatment and Survival
Four studies evaluated the effects of Medicaid coverage disruptions on receipt of treatment (44,51–53), and 7 studies evaluated
the effects of disruptions on survival (34,35,40,42,44,45,51).
Details of study populations, settings, measures of coverage

Discussion
In this study, we conducted a systematic review of the published literature to assess the role of health insurance coverage
disruptions on receipt of cancer care and outcomes in the
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with longer durations of insurance coverage. Shorter durations
of insurance coverage were statistically significantly associated
with less frequent receipt of HPV vaccination among adolescent
girls (39). Several studies reported a dose-response relationship
between coverage duration and greater receipt of prevention
and screening (28,32,39).
Coverage disruption was not statistically significantly associated with receipt of screening in 1 study with a relatively
small sample (n ¼ 333) that included adults older than age
65 years (who are generally age-eligible for continuous Medicare
coverage) (30). Associations between coverage disruptions and
colorectal cancer screening (eg, fecal occult blood test, flexible
sigmoidoscopy, or colonoscopy) in men and women were null
(27,30,38). Two of the 4 studies did not include colonoscopy
(27,38), currently the most common colorectal cancer screening
modality.

5852 women and men aged
25-64 y newly diagnosed
with BC, CRC, or cervical
or lung cancer

598 women aged 29-64 y
with newly diagnosed BC

1063 women aged <65 y
with newly diagnosed
cervical cancer

96 220 women and men
aged <65 y newly diagnosed with colon, esophageal, lung, ovarian,
pancreatic, or gastric
cancers

782 women aged <65 y
newly diagnosed with
cancers of cervix, uterus,
ovary, and vulva or
vagina

52 774 AYAs aged 15-39 y
newly diagnosed with 9
common cancers, including BC, CRC, and thyroid,
melanoma, testicular,
non-Hodgkin lymphoma,

Bradley et al., 2003b (40)

Bradley et al., 2004 (43)

Dawes et al., 2014 (44)

Doll et al., 2016 (45)

Keegan et al., 2019 (46)

Sample size, No.

California Cancer Registry
data (2005–2014), linked
to Medicaid enrollment
(2004-2014)

North Carolina Central
Cancer Registry Medicaid enrollment,
2003-2008. Follow-up
through 2010

California Cancer Registry,
California’s Patient
Discharge Database, and
Medicaid enrollment
files, 2002-2008

Michigan Cancer Registry Medicaid enrollment,
1996-1997

REVIEW

(continued)

Percentage enrolled in Medicaid after diagnosis not reported. Compared with those enrolled in Medicaid >1 mo before diagnosis,
those enrolled after diagnosis more likely
diagnosed at late stage (4% vs 8%, P < .05)
59.5% of patients with Medicaid discontinuously enrolled
Compared with those continuously enrolled
in Medicaid, those discontinuously enrolled
more likely to have advanced stage of diagnosis for colon (29.8% vs 41.7%), esophageal
(51.6% vs 58.5%), lung (67.8% vs 78.5%), ovarian (59.8% vs 69.4%), pancreatic (66.1% vs
69.5%), and gastric (52.6% vs 61.6%) cancers
in unadjusted analyses
38.6% enrolled in Medicaid after diagnosis
Early stage (local) vs adTiming of coverage meaAfter propensity matching, postdiagnosis envanced stage (regional
sured as Medicaid enrollrollment group more likely to have adand distant) from registry
ment after diagnosis vs
vanced stage (OR ¼ 1.46, 95% CI ¼ 1.03 to
Medicaid enrollment pre2.05). When stratified by cancer site, effect
diagnosis (1-6 mo begreatest in uterine cancer (OR ¼ 1.74, 95%
fore diagnosis)
CI ¼ 0.87 to 3.47) and cervix (OR ¼ 1.50, 95%
CI ¼ 0.91 to 2.49), but not statistically
significant
AJCC stage I vs II-IV or AJCC Of Medicaid patients, 34.2% peridiagnosis enTiming of coverage and
stage I-II vs III-IV from
coverage gap measured
rolled <1 mo and 15.7% discontinuously
as Medicaid peridiagnosis
enrolled
registry
enrolled <1 mo, or disCompared with AYAs with private insurance,
continuous Medicaid vs
AYAs who gained Medicaid coverage at dicontinuous Medicaid (enagnosis 2.2-2.5 times more likely later stage
rolled 5 mo before
(stage II-IV vs I: OR ¼ 2.46, 95% CI ¼ 2.26 to

Early stage (in situ or localTiming of coverage meaized) vs late stage (resured as Medicaid-engional, distant, or
rolled after diagnosis vs
invasive/unknown) from
Medicaid-enrolled for >1
registry
mo at diagnosis
Early-stage (in situ or local)
Timing of coverage meavs late stage (regional,
sured as Medicaid-endistant, or invasive/unrolled after diagnosis vs
known) from registry
Medicaid-enrolled for >1
mo at diagnosis
Discontinuous Medicaid en- Early stage (localized and
regional) vs advanced
rollment (did not have
stage (remote) from
consecutive 6 mo coverregistry
age prediagnosis) vs continuous Medicaid
enrollment (>6 mo
prediagnosis)

36% enrolled in Medicaid after diagnosis
Postdiagnosis Medicaid enrolled more likely
to have late-stage diagnosis compared with
previously enrolled for BC (1.328, 95% CI ¼
0.95 to 1.67), cervical cancer (2.96, 95% CI ¼
1.85 to 4.75), CRC (2.08, 95% CI ¼ 1.30 to 3.33,
and lung cancer (3.40, 95% CI ¼ 2.13 to 5.43)
22.1% enrolled in Medicaid after diagnosis
Lack of Medicaid coverage before diagnosis
increased odds of late-stage diagnosis
(HR ¼ 1.71, 95% CI ¼ 1.13 to 2.58, P < .05)

Early stage (in situ or localized) vs late stage (regional, distant, or
invasive/unknown) from
registry

Timing of coverage measured as Medicaid-enrolled after diagnosis vs
Medicaid-enrolled for >1
mo at diagnosis

Michigan Cancer Registry Medicaid enrollment,
1996-1997

Michigan Cancer Registry Medicaid enrollment,
1996-1997

Key findings

Outcome measures

Insurance coverage
measures

Setting, data source, and
year
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2576 women aged 15 y,
newly diagnosed with BC
or cervical cancer

26 426 women aged 40-64 y
newly diagnosed with invasive BC

Koroukian et al., 2017 (34)

Hodgkin lymphoma, cervical, and ovarian

Sample size, No.

Early stage (in situ or localized) vs advanced stage
(regional or distant) from
registry

Localized vs advancedstage (regional or distant)
from registry
Timing of Medicaid coverage peridiagnosis, (enrolled at diagnosis or <3
mo of diagnosis), BCCEDP
repeat user vs enrolled
3 mo before diagnosis

Ohio Cancer Registry,
Medicaid enrollment
data, and BCCEDP database (diagnoses 20022008, deaths 2002-2010)

Outcome measures

Medicaid vs non-Medicaid
coverage, and timing of
Medicaid enrollment:
prediagnosis (enrolled >3
mo preceding diagnosis),
peridiagnosis (2 mo preceding diagnosis), and
postdiagnosis (enrolled
3 mo after diagnosis)

diagnosis) and private or
military coverage

Insurance coverage
measures

Ohio Cancer Registry;
Medicaid Enrollment
data, 1996-1998

Setting, data source, and
year

(continued)

2.69; III-IV vs I-II: OR ¼ 2.16, 95% CI ¼ 2.00 to
2.33) and AYAs with discontinuous
Medicaid 1.7-1.9 times more likely later
stage (stage II-IV vs I: OR ¼ 1.93, 95% CI ¼
1.70 to 2.18; III-IV vs I-II: OR ¼ 1.74, 95% CI ¼
1.56 to 1.95) in adjusted analyses. Findings
statistically significant for all 9 cancers. In
analyses limited to AYAs with Medicaid,
continuous coverage improved odds of earlier stage diagnosis compared with both
peridiagnosis enrollment or discontinuous
enrollment
Of patients with Medicaid, 70.8% enrolled
prediagnosis, 25.2% peridiagnosis, and 4.0%
postdiagnosis
Compared with prediagnosis enrollment,
peridiagnosis group had increased risk of
advanced cancer overall (AOR ¼ 3.8, 95%
CI ¼ 2.8 to 5.0) and for BC (AOR ¼ 3.8, 95%
CI ¼ 2.8 to 5.2) and cervical cancers (AOR ¼
3.6, 95% CI ¼ 1.8 to 7.3)
Postdiagnosis enrollment increased risk of
advanced cancer compared with prediagnosis group (AOR ¼ 2.2, 95% CI ¼ 1.2 to 4.0). By
cancer site, advanced disease higher for BC
(AOR ¼ 3.8, 95% CI ¼ 2.8 to 5.2; AOR ¼ 2.1,
95% CI ¼ 1.1 to 4.1) and cervical cancers
(AOR ¼ 3.6, 95% CI ¼ 1.8 to 7.3; AOR ¼ 2.8,
95% CI ¼ 0.5 to 14.2) for peri- and postdiagnosis groups compared with prediagnosis
group, respectively
31.6% of patients in peri- or postdiagnosis
group
Peridiagnosis group more likely to be diagnosed with advanced-stage disease (AOR ¼
2.20; 95% CI ¼ 1.83 to 2.66)
Compared with Medicaid prediagnosis,
BCCEDP 1-time users more likely to be diagnosed late stage (AOR ¼ 1.48, 95% CI ¼ 1.17
to 1.87) but repeat users similar stage at diagnosis (AOR ¼ 0.83, 95% CI ¼ 0.59 to 1.18)

Key findings
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Koroukian, 2003 (33)

Reference
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4682 women aged <65 y
newly diagnosed with invasive cervical cancer

10 016 women aged 30-64 y,
newly diagnosed with BC

4558 women and men aged
15-64 y, newly diagnosed
with melanoma

5009 women and men aged
<65 y with newly diagnosed BC, CRC, or cervical, lung, or prostate
cancer

Perkins et al., 2000 (48)

Pollitt et al., 2008 (49)

Ramsey et al., 2008 (50)

Sample size, No.

Early stage (in situ and localized) vs late stage (any
extension beyond the
breast, including regional
lymph nodes) from
registry

Localized and advancedstage (regional or distant)
from registry

In situ, localized, regional,
and distant from registry

Timing of prediagnosis
Medicaid enrollment: 1)
entire 12 mo before diagnosis; 2) part of 12 mo before diagnosis; and 3) not
covered by Medicaid in
any of 12 mo before
diagnosis
Medicaid enrollment at diagnosis (yes/no); timing
of enrollment: 1) first enrolled at month of diagnosis, 2) enrolled during
month of diagnosis and
1-11 mo before diagnosis,
3) enrolled during month
of diagnosis and 12 mo
before diagnosis, and 4)
not enrolled at diagnosis

Timing of Medicaid enrollment measured as previously enrolled (3 mo
before diagnosis) vs enrolled at diagnosis (<3
mo before diagnosis to 6
mo after diagnosis)

California Cancer Registry,
and linked Medi-Cal enrollment files, 1992-1993

California Cancer Registry
and linked Medicaid enrollment files, 1998-1999

Washington State Cancer
Registry and Medicaid
enrollment 1997-2002

REVIEW

Early stage (localized) vs
late stage (regional and
remote) from registry

Timing of Medicaid coverage measured as prediagnosis: 1) first enrolled in
month of diagnosis; 2)
enrolled at time of diagnosis and for 1-11 mo in
year before diagnosis (intermittently enrolled); 3)
enrolled 12 mo before diagnosis, including at diagnosis; and 4) not
enrolled at diagnosis

California Cancer RegistryMedicaid enrollment;
1996-1999

Outcome measures

Insurance coverage
measures

Setting, data source, and
year

(continued)

16.0% enrolled in Medicaid during month of
diagnosis, 23.6% 1-11 mo before diagnosis,
and 60.4% continuously enrolled 1 y before diagnosis
Compared with non-Medicaid coverage
(uninsured and insured), adjusted odds ratios for late- or unknown-stage diagnosis
were: 2.8 (95% CI ¼ 1.9 to 4.2) for those enrolled at diagnosis, 1.34 (95% CI ¼ 1.00 to
1.80) for those enrolled 1-11 mo before diagnosis, and 1.08 (95% CI ¼ 0.89 to 1.33) for
those continuously enrolled in Medicaid for
1 y
18.0% enrolled in Medicaid at time of
diagnosis
Compared with non-Medicaid (uninsured/privately insured combined), odds ratio for
late-stage disease among all women on
Medi-Cal was 1.67 (95% CI ¼ 1.41 to 1.97) but
was reduced by 42% to 1.39 (95% CI ¼ 1.15 to
1.67) when women without benefits before
diagnosis excluded
Among Medicaid-insured, 13.7% first enrolled
month of diagnosis; 31.6% enrolled for 1 -11
mo (continuously or noncontinuously) before diagnosis; and 54.7% enrolled entire
past year.
Compared with non-Medicaid coverage
(uninsured and insured combined), adjusted odds ratios for late-stage diagnosis
were: 13.64 (95% CI ¼ 4.43 to 41.98) for those
enrolled at diagnosis, 2.77 (95% CI ¼ 1.28 to
5.99) for those enrolled 1-11 mo before diagnosis, and 1.30 (95% CI ¼ 0.64 to 2.64) for
those continuously enrolled in Medicaid 1
57.2% of Medicaid patients enrolled <3 mo
before diagnosis
Those enrolled in Medicaid at diagnosis more
likely to have regional and distant stage disease at diagnosis than previously enrolled
(P < .001) and more likely to disenroll at 12
mo (76.4% vs 23.6%)

Key findings

Downloaded from https://academic.oup.com/jnci/article/112/7/671/5821430 by Thomas Jefferson University user on 07 October 2021

O’Malley et al., 2006 (47)

Reference
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Setting, data source, and
year
Timing of coverage measured as longer term/
established Medicaid (enrolled 6 mo at diagnosis)
or newly enrolled
Length of Medicaid enrollment (11, 6 to <11, 1 to
<6, <1 mo)
Continuous enrollment status (defined as no gaps
>30 d in prior year)

Insurance coverage
measures
Key findings

25.3% with Medicaid newly enrolled at
diagnosis
For all cancer sites, statistically significantly
higher proportions of Medicaid patients
and especially newly enrolled Medicaid
patients diagnosed with late-stage cancer
compared with non-Medicaid patients (BC,
20% and 23% vs 11%, P < .001; CRC, 46% and
56% vs 42%, P ¼ .025; ICC, 41% and 38% vs
30%, P < .001)
For all cancers combined, shorter enrollment
length was associated with higher likelihood of late-stage diagnosis (57.5%, 48.1%,
39.9%, and 41.5 for <1, 1 to <6, 6 to <11, and
11 mo, respectively. P < .001)
No statistically significant differences in
stage at diagnosis observed comparing
those continuously covered and with coverage disruptions (46.3% vs 45.2%, P ¼ .86)

Outcome measures
Early stage (in situ or localized) or late (regional or
distant) from registry

AJCC ¼ American Joint Committee on Cancer; AOR ¼ Adjusted odds ratio; AYA ¼ Adolescents and young adult; BC ¼ breast cancer; BCCEDP ¼ Breast and Cervical Cancer Early Detection Program; CI ¼ confidence interval; CRC ¼ co-

19 209 women aged 21-64 y New Jersey Cancer Registry
and New Jersey Medicaid
newly diagnosed with BC,
Management
CRC, or cervical cancer
Information System,
2012-2014

Sample size, No.
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lorectal cancer; HR ¼ hazard ratio; ICC ¼ invasive cervical cancer; OR ¼ odds ratio; RR ¼ risk ratio.

a

Tsui et al., 2018 (51)

Reference
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2048 women aged
19-63 y with newly
diagnosed BC

598 women aged 2964 y with newly
diagnosed BC

13 740 women and
men aged <65 y
newly diagnosed
with BC, CRC, or
lung cancer

Bradley et al., 2003b
(40)

Bradley et al., 2005
(42)

Sample size, No.

Timing of coverage
measured as
Medicaid-enrolled for
>1 mo at diagnosis,
Medicaid-enrolled after diagnosis, or nonMedicaid (including
uninsured or privately
insured)

Michigan Cancer
Registry - Medicaid
enrollment, 1996-1997
and follow-up
through 2003

REVIEW

Timing of coverage
measured as
Medicaid-enrolled before diagnosis vs
Medicaid-enrolled after diagnosis and
Medicaid-enrolled as
part of BCCEDP
Prevention and
Treatment Act, disabled, and other
Medicaid
Timing of coverage
measured as
Medicaid-enrolled for
>1 mo at diagnosis,
Medicaid-enrolled after diagnosis

Georgia Cancer Registry
-Medicaid enrollment
and BCCEDP data
2002–2004 with 2-y
follow-up

Michigan Cancer
Registry - Medicaid
enrollment, 19961997. Follow-up until
1998

Insurance coverage
measures

Setting, data source, and
year

All-cause mortality
Vital status from
registry

(continued)

51.7% enrolled after diagnosis and 48.9% continuously
enrolled
Compared with women enrolled in Medicaid after cancer
diagnosis, those previously enrolled more likely to receive
any treatment (OR ¼ 2.41, 95% CI ¼ 1.28 to 4.56) or any definitive surgery (OR ¼ 7.66, 95% CI ¼ 5.06 to 11.59) in adjusted analyses
Compared with “other” and disabled Medicaid enrollment,
BCCEDP enrolled more likely to receive any treatment (OR
¼ 4.71, 95% CI ¼ 2.48 to 8.96), any drug regimen (OR ¼ 3.58,
95% CI ¼ 2.32 to 5.51), and any definitive surgery (OR ¼
2.52, 95% CI ¼ 1.74 to 3.66) in adjusted analyses
22.1% enrolled in Medicaid after diagnosis
Among those aged <65 y, mortality risk was higher for
those without Medicaid coverage at diagnosis (HR ¼ 1.67,
95% CI ¼ 1.09 to 2.56, P < .05). Overall, late stage was
strongest predictor of increased risk of mortality (HR ¼
4.40, 95% CI ¼ 2.8 to 6.9, P < .05).
When late-stage disease added to model, effects of
Medicaid insurance no longer statistically significant
42% enrolled in Medicaid after diagnosis
Median survival in postdiagnosis enrollment group was 19
mo (95% CI ¼ 17 to 22 mo) compared with 38 mo (95% CI ¼
32 to 44 mo) in prediagnosis enrollment group. When
assessed by cancer site and stage, HR for Medicaid enrolled after diagnosis vs non-Medicaid generally higher
for women with early-stage BC (HR ¼ 3.10, 95% CI ¼ 2.35
to 4.10), CRC (HR ¼ 2.78, 95% CI ¼ 1.87 to 4.14), and lung
cancer (HR ¼ 1.64, 95% CI ¼ 1.19 to 2.26) than late-stage BC
(HR ¼ 2.43, 95% CI ¼ 1.94 to 3.04), CRC (HR ¼ 2.18, 95% CI ¼
1.59 to 2.98), and lung cancer (HR ¼ 1.28, 95% CI ¼ 1.08 to
1.52)
Receipt of lumpectomy,
mastectomy, any
drug regimen (hormonal or chemotherapy), radiation, and
any treatment from
diagnosis to end of
follow-up. Receipt of
treatment measured
by claims

All-cause mortality
Vital status from
registry

Key findings

Outcome measures
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Reference
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96 220 women and
men aged <65 y
newly diagnosed
with colon, esophageal, lung, ovarian, pancreatic, or
gastric cancers

782 women aged <65
y newly diagnosed
with cancers of
cervix, uterus,
ovary, and vulva/
vagina

12 703 women and
men aged 15-54 y
newly diagnosed
with bladder, colon, lung, and testicular cancers,
melanoma, pediatric malignancies, or Hodgkin

Doll et al., 2016 (45)

Koroukian et al.,
2012 (35)

Sample size, No.

Ohio Cancer Registry;
Ohio Medicaid
Enrollment data,
1996-2002. Follow-up
through 2007

Survival and 5-y
mortality
Vital status from
registry

(continued)

43.9% of Medicaid enrollees peri-/postdiagnosis.
Adjusted AORs for 5-y disease-specific mortality were 1.58
for prediagnosis Medicaid enrollees (95% CI ¼ 1.25 to 1.99)
and 2.43 for peri-/postdiagnosis Medicaid enrollees (95%
CI ¼ 1.94 to 3.04) compared with non-Medicaid population
with either private coverage or uninsured (for both, P <
.001). Effects of coverage disruptions not reported by cancer site

All-cause mortality (median follow-up ¼ 22
mo)
Vital status from
registry

Timing of coverage
measured as
Medicaid enrollment
before diagnosis (1
mo of coverage in 6
mo before diagnosis)
vs Medicaid enrollment after diagnosis
Timing of coverage
measured as
Medicaid prediagnosis (3 mo coverage
before diagnosis) vs
Medicaid peri-/postdiagnosis (enrollment
during <3-mo window before or after
diagnosis)

North Carolina Central
Cancer Registry Medicaid enrollment,
2003-2008. Follow-up
through 2010

59.5% of patients with Medicaid discontinuously enrolled
Compared with those continuously enrolled in Medicaid,
discontinuously enrolled patients less likely to receive definitive surgery for colon (70.5% vs 61.9%, P < .001), lung
(17.7% vs 15.3%, P ¼ .012), and gastric (37.2% vs 31.0%, P ¼
.015) cancers. Adjusted models not reported for esophagus, ovary, and pancreas cancers. Statistically significant
1-y mortality benefit in patients with continuous (vs discontinuous) Medicaid coverage in 3 cancer types: colon
(23.0% vs 19.1%, P ¼ .001), lung (66.7 vs 62.4%, P ¼ .002),
and gastric (57.8 vs 49.0%, P ¼ .001) cancers. No statistically significant mortality differences were observed for
esophagus (66.6% vs 70.4%, P ¼ .33), ovary (21.5% vs 22.1%
P ¼ .80), and pancreas (76.1% vs 75.7%, P ¼ .87) cancers in
adjusted analyses
38.6% enrolled in Medicaid after diagnosis
Lack of prediagnosis Medicaid coverage had mortality HR of
1.28 (95% CI ¼ 0.99 to 1.65) when stage not included and
mortality HR of 1.19 (95% CI ¼ 0.92 to 1.53) when adjusted
for stage

Receipt of definitive operation status from
hospital discharge,
death within 1 y of
diagnosis
Vital status from
registry

Continuous Medicaid
enrollment (>6 mo
prediagnosis) vs discontinuous Medicaid
enrollment (did not
have 6 consecutive
mo coverage
prediagnosis)

California Cancer
Registry, California’s
Patient Discharge
Database, and
Medicaid enrollment
2002-2008

Key findings

Outcome measures

Insurance coverage
measures

Setting, data source, and
year
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New Jersey Cancer
Registry and New
Jersey Medicaid
Management
Information System,
2012-2014; survival
through 2016

Treatment delay (>90 d
after diagnosis) from
claims, and 2-y
survival
Vital status from
registry

Receipt of first course of
treatment (surgery,
radiation, and chemotherapy) from cancer
diagnosis to end of
follow-up from claims

Continuous Medicaid
from diagnosis to
12 mo postdiagnosis:
vs not continuously
enrolled (gaps in coverage of 2 mo) vs
continuously
Medicaid enrolled (no
gaps in coverage or
gaps in coverage for
<2 mo)
Timing of coverage
measured as longer
term/established
Medicaid patients (enrolled 6 mo at diagnosis), newly enrolled
Medicaid patients (<6
mo). Duration of coverage measured as
length of Medicaid
enrollment (11, 6 to
<11, 1 to <6, <1 mo)
vs continuous enrollment status (no gaps
>30 d in prior year).

California and Georgia
State Cancer Registry
- California and
Georgia Medicaid
Claims, 2002-2006.
Follow-up time not
stated

25.3% with Medicaid newly enrolled at diagnosis
Newly enrolled patients higher likelihood of treatment delay for BC (OR ¼ 8.79, 95% CI ¼ 5.91 to 13.10), cervical cancer (OR ¼ 2.47, 95% CI ¼ 1.00 to 6.15), and CRC (OR ¼ 3.02,
95% CI ¼ 1.94 to 4.71) cancers
Shorter enrollment time associated with treatment delay
(76.3%, 41.6%, 46.5%, and 51.9 for <1 mo, 1 to <6 mo, 6 to
<11 mo, and 11 mo, respectively; P < .001)
No statistically significant differences in treatment delay
between continuously covered and coverage disruptions
(46.9% vs 51.3%, P ¼ .45)
Newly enrolled in Medicaid had lowest 2-y survival compared with established Medicaid and patients without
Medicaid coverage (private insurance and uninsured;
P < .001)

31.6% enrolled peri-/postdiagnosis.
Peridiagnosis Medicaid worse overall and cancer-specific
survival compared with non-Medicaid (P < .05).
Peridiagnosis Medicaid similar overall (HR ¼ 0.87, 95% CI
¼ 0.74 to 1.02) and cancer-specific (HR ¼ 0.92, 95% CI ¼
0.76 to 1.11) survival compared with prediagnosis
Medicaid.
Compared with Medicaid prediagnosis, BCCEDP 1 time and
repeat users better overall (AHR ¼ 0.60, 95% CI ¼ 0.45 to
0.80 and AHR ¼ 0.27, 95% CI ¼ 0.13 to 0.54, respectively)
and cancer-specific survival (AHR ¼ 0.77, 95% CI ¼ 0.57 to
1.06 and AHR ¼ 0.36, 95% CI ¼ 0.16 to 0.80, respectively)
9.3% and 31.5% patients alive 12 mo after diagnosis not continuously enrolled in Medicaid after diagnosis in
California and Georgia, respectively
Compared with continuously enrolled, no statistically significant differences for receipt of surgery (OR ¼ 1.05, 95%
CI ¼ 0.72 to 1.56), radiation (OR ¼ 0.93, 95% CI ¼ 0.63 to
1.37), and chemotherapy (OR ¼ 1.49, 95% CI ¼ 1.00 to 2.27)
with those not continuously insured

Key findings

REVIEW

BC ¼ breast cancer; BCCEDP ¼ Breast and Cervical Cancer Early Detection Program; CI ¼ confidence interval; CRC ¼ colorectal cancer; HR ¼ hazard ratio; OR ¼ odds ratio; AOR ¼ adjusted odds ratio.

19 209 women newly
diagnosed with
BC, CRC, or cervical cancer

Tsui et al., 2018 (51)

Overall and cancer-specific survival
Vital status from
registry

Outcome measures

Timing of coverage
measured as
Medicaid status (enrolled 3 mo before
diagnosis or peridiagnosis, [enrolled at diagnosis or <3 mo of
diagnosis]), BCCEDP
repeat user

Insurance coverage
measures

Ohio Cancer Registry,
Medicaid enrollment
data, and BCCEDP
data. Patients diagnosed 2002-2008;
deaths through 2010

Setting, data source, and
year
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Adults aged 18-64 y
from California (N
¼ 691) and Georgia
(N ¼ 225) newly diagnosed with
head and neck
cancer and alive
12 mo after
diagnosis

and non-Hodgkin
lymphoma
26 426 women aged
40-64 y newly diagnosed with invasive BC

Sample size, No.

Subramanian and
Chen, 2013 (53)

Koroukian et al.,
2017 (34)

Reference
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REVIEW

705 decedents previously diagnosed with
cancer between ages
of 15 and 29 y

Mack et al., 2015 (55)

New York State Cancer
Registry - Medicaid
Enrollment, 20042011. Deaths by Dec.
31, 2011

Hospice use from claims

1) Hospice use; 2) EOL
intensity measured
by chemotherapy use
within 14 d of death,
care in ICU within 30
d of death, more than
1 ER visit within 30 d
of death, hospitalization within 30 d of
death from claims

Medicaid enrollment between month of diagnosis and month of death or
censoring (continuous,
enrolled more than 50%
of the time but not continuously, enrolled <50%
of time)

Timing of coverage measured as 1) enrolled in
Medicaid before diagnosis or around time of diagnosis (duration of
enrollment before diagnosis not stated); 2)
Medicaid enrollment between month of diagnosis and month of death
(continuous, enrolled
>50% of the time but not
continuously, enrolled
<50% of time)

California and New York
State Cancer Registry
- California and New
York Medicaid
Enrollment, 20022006. Follow-up
through 2017

CI ¼ confidence interval; EOL ¼ end-of-life; ER ¼ emergency room; ICU ¼ intensive care unit; OR ¼ odds ratio.

4797 California patients
and 4001 New York
patients aged 21-64 y
with newly diagnosed
stage IV lung cancer

Mack et al., 2013 (54)

2.5%, 12.7%, 7.8%, 5.3%, 4.7%, and 67.0% of decedents enrolled in Medicaid at month of death, 1-3, 4-6, 7-9, 10-12,
or >12 mo prior death, respectively.
Overall, longer time of Medicaid enrollment was associated
with higher monthly total expenditures. Monthly expenditures were $770, $1105, $1674, $1941, $1987, and $1905
for those enrolled at month of death, 1-3, 4-6, 7-9, 10-12,
or >12 mo before death, respectively. Year of dollars not
stated
69%, 21%, and 10% patients continuously enrolled in
Medicaid, enrolled >50% of time but not continuously, enrolled <50% of time in California, respectively; 64%, 24%,
and 12% patients continuously enrolled in Medicaid, enrolled >50% of time but not continuously, enrolled <50%
of time in New York, respectively.
In both states, compared with continuously enrolled,
patients enrolled >50% of time but not continuously (OR
¼ 0.82, 95% CI ¼ 0.69 to 0.98) or enrolled <50% of time (OR
¼ 0.45, 95% CI ¼ 0.35 to 0.57) had lower hospice use
15.4% of patients enrolled in Medicaid at or after cancer diagnosis. 65.5%, 28.5%, and 6.0% patients continuously enrolled in Medicaid, enrolled >50% of time but not
continuously, enrolled <50% of time, respectively.
Compared with patients enrolled before cancer diagnosis,
those enrolled at or after diagnosis had lower hospice use
(OR ¼ 0.26, 95% CI ¼ 0.08 to 0.83). Compared with continuously enrolled, patients who enrolled >50% of time but
not continuously (OR ¼ 0.36, 95% CI ¼ 0.23 to 0.56) or enrolled <50% of time (OR ¼ 0.22, 95% CI ¼ 0.10 to 0.51) were
less likely to have intensive EOL care
Per person per month
enrolled total medical
expenditures from
claims

Duration of coverage measured as Medicaid enrollment months prior death
(enrolled at month of
death, or 1-3, 4-6, 7-9, 1012, or >12 mo prior
death)

Ohio Medicaid
Enrollment and
claims data: death
certificate, 1992-2002

Key findings

Outcome measures

Insurance coverage
measures

Setting, data source, and
year
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a

44 509 decedents with
cancer as underlying
cause of death (no age
restriction)

Sample size, No.

Koroukian et al.,
2006 (36)

Reference

Table 5. Health insurance coverage disruptions and other health services use and health-care spendinga
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We did not identify any published studies of effective interventions at the patient, provider, employer, health system, policy, or regulatory levels that help patients maintain continuous
health insurance coverage throughout the cancer control continuum. Several studies testing interventions to improve coverage continuity are in progress (60,61), however. For example,
within federally qualified health centers in multiple states, the
introduction of electronic health record tools for identifying
patients in advance of their Medicaid recertification to ensure
continuity of coverage is being evaluated for potential improvements in receipt of cancer prevention and screening (60).
Another ongoing intervention study involves a multi-employer
Taft-Hartley Trust Fund that provides health benefits to hourly,
low-wage employees who would otherwise not have health insurance coverage. This ongoing study is testing provision of continuous health benefits coverage for low-wage employees after a
cancer diagnosis and incentives for the use of high-quality cancer
care providers through travel benefits and narrow networks (61).
Further development and testing of interventions to improve coverage continuity in public and private settings using experimental
designs, especially for patients at risk of coverage disruptions,
will be important.
Most studies in this review were conducted in single states
and used cancer registry–Medicaid enrollment and claims linkages to evaluate the effects of coverage disruptions. Although
the prevalence of coverage disruptions varied, among those
with Medicaid coverage, up to 59.5% of newly diagnosed
patients enrolled only at or after their cancer diagnosis (42,50).
Findings that peri- and postdiagnosis enrollment were consistently associated with worse outcomes suggest that at least
some of the worse survival associated with Medicaid compared
with private insurance coverage observed elsewhere (4,7) may
be attributable to the impact of coverage disruptions.
Coverage disruptions were consistently associated with advanced stage and worse survival for cancers with effective
screening tests—namely, breast, cervical, and colorectal cancers
(33,34,40–43,46–48,50,51). Two studies included in this review
evaluated the effects of breast and cervical cancer screening
through BCCEDP before Medicaid enrollment in 2 states (34,52),
but they could not fully disentangle the potentially positive
effects of screen detection vs the potentially negative effects of
limited access to usual source of care or symptom evaluation
associated with lack of insurance coverage before diagnosis. A
large body of research has consistently found that in addition to
health insurance coverage, having a usual source of health care
is strongly associated with receipt of breast and cervical cancer
screening (5), but neither study reported this information.
Medicaid patients with coverage disruptions have also been
reported to be more likely to disenroll in the year after their cancer diagnosis (50), which may adversely affect completion of
recommended treatment(s) and access to and receipt of highquality survivorship care. Care received after Medicaid disenrollment, including assessment for recurrence, surveillance for
new cancers, symptom management, or end-of-life care, is unknown. Among adults with private insurance coverage, a cancer
diagnosis and its treatment(s) can lead to time away from work,
job loss, and loss of employer-sponsored health insurance coverage. The longitudinal effects of coverage disruptions across
the cancer control continuum are not easily addressed with current data infrastructure, however.
Improvements in cancer registry and health insurance data
infrastructure resulting in comprehensive longitudinal data can
help to quantify the effects of coverage disruptions and differences in state-level policies, such as Medicaid generosity,
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United States. We identified 29 observational published studies
and found that coverage disruptions were common and despite
heterogeneity in populations and measures, disruptions were
consistently statistically significantly associated with less frequent receipt of cancer care and poorer cancer outcomes.
Specifically, those with coverage disruptions were less likely to
receive cancer prevention or screening (27–29,32,37,39), and if
diagnosed with cancer, they were more likely to have advanced
disease (33,34,40,41,43–51), be less likely to receive treatment
(44,52,54,55), and have worse survival (34,35,40,42,44,45,51) than
their counterparts without coverage disruptions. Findings were
consistent across multiple cancer sites. Additionally, several
studies reported a dose-response relationship between coverage duration and receipt of prevention (39), screening (28,32),
earlier stage (51), and timeliness of treatment (51). The consistency of these findings across the cancer control continuum
highlight the importance of minimizing health insurance coverage disruptions in addressing cancer disparities and promoting
health equity.
Policies and trends that exacerbate coverage disruptions may
increase disparities. The recent emergence of work requirements
for some state Medicaid programs might increase the prevalence
of coverage disruptions. Research conducted in Arkansas suggests that Medicaid work requirements are associated with disenrollment of eligible residents without increases in employment
(56). Broader employment trends, such as the increased prevalence of “gig” workers (eg, Uber, Lyft, TaskRabbit) (57) and associated income fluctuations, may increase disruptions in coverage
among the nongroup self-insured facing frequent changes in eligibility for subsidies and coverage affordability. Despite the importance of private health insurance coverage for the working
age population in the United States, we did not identify any studies specifically addressing the effects of private health insurance
coverage disruptions on cancer care and outcomes. Preliminary
research suggests that for cancer survivors, the magnitude of association between disruptions in private health insurance and
worse access to and receipt of care is similar to that for disruptions in public insurance (58); additional research is warranted in
both public and private coverage settings.
Conversely, policies that facilitate health insurance coverage
continuity may minimize disparities. Increased availability of
health insurance coverage options through the ACA, including
individual purchase through the ACA Marketplace, availability
of subsidies to reduce premium costs, expansion of dependent
coverage on parents’ private plans for young adults until age 26
years, and Medicaid eligibility in some states, might minimize
disruptions and facilitate continuous health insurance coverage. State policies, such as the proposed New York Medicaid
waiver to allow prisoners with health conditions to receive
Medicaid coverage before and following their release from jail,
may also help minimize disruptions and maintain care and provider network continuity. To date, most research evaluating the
effects of the ACA has focused on coverage gains, and none
assessed the effects of the ACA on reducing the prevalence or
frequency of coverage disruptions and effects on cancer care
and outcomes. A recent study found Medicaid expansion was
associated with reductions in coverage disruptions in the lowincome general population living in expansion compared with
nonexpansion states (59). Given the rapidly changing health insurance landscape in the United States and the maturation of
data post-ACA, evaluating the effects of specific provisions of
the ACA, especially Medicaid expansions, on coverage disruptions and health outcomes will be important for future research
using quasi-experimental designs.
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Nonetheless, we were able to qualitatively synthesize a large
body of research and identify research gaps and opportunities
for data infrastructure improvements.
In summary, we found that health insurance coverage disruptions were consistently adversely associated with receipt of
cancer prevention and screening and among those diagnosed
with cancer, later stage of disease, delayed treatment if any,
and poorer survival. Future research identifying modifiable factors at the patient, employer, state, and federal policy levels to
minimize coverage disruptions may also reduce cancer disparities. Improved data infrastructure and quasi-experimental and
experimental study designs will be important for evaluating the
associations of federal and state policies on coverage disruptions and care and outcomes.
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physician reimbursement, managed care penetration, and timing of Medicaid eligibility recertification, on receipt of cancer
care and outcomes. Current individual state-level linkages,
such as the ones identified in this review, cannot be used to
evaluate the effects of differences between states in state-level
policies. Centralized data linkages across multiple states, such
as SEER-Medicaid, could transform the ability to evaluate
Medicaid policies, especially as the updated version of the national Medicaid data, Transformed Medicaid Statistical
Information System, becomes available (62). Currently, more
than 15 states have legislation requiring aggregation of allpayer claims data (APCD); as these data become increasingly
available and research-ready, state-level cancer registry–APCD
linkages may be especially useful for evaluating the effects of
private coverage disruptions and cancer outcomes and potentially, differences in state policies. As APCD data become standardized across states, centralized cancer registry data linkages
across multiple states with APCD could further these efforts.
We identified many limitations in existing studies, including
inconsistency of coverage disruption measures and lack of information about prior coverage (private or uninsured) or reasons for prior uninsurance or coverage change among those
newly enrolled in Medicaid at or after cancer diagnosis. Because
previous private insurance coverage would be expected to convey better access to care, any misclassification of previously
uninsured patients suggests that the effect of gaining coverage
only after diagnosis is understated. Similarly, some studies
compared patients gaining Medicaid coverage at diagnosis to all
non-Medicaid-covered patients, including privately insured and
uninsured, which would underestimate the magnitude of associations between disruptions and more advanced stage or survival following diagnosis. Generalizability of findings of the
adverse effects of coverage disruptions in populations of
Medicaid enrollees to populations with private health insurance
coverage may be limited.
All studies included in this systematic review were observational, and we cannot infer causality between health insurance
coverage disruptions and worse care receipt and outcomes.
However, all studies included comparison groups and despite
the heterogeneity of measures of coverage disruptions, findings
were consistent across studies and the magnitude of many
associations was large. Nonetheless, studies with experimental
designs are needed to infer causality of coverage disruptions
and intervention effects to minimize disruptions and receipt of
cancer care and health outcomes. In addition, evaluation of
trends and comparisons of findings from specific states at different time points are limited by differences in state-level policies (eg, Medicaid eligibility threshold, recertification timing),
socioeconomic characteristics, cancer sites, and heterogeneity
of definitions of coverage disruptions.
An important strength of this systematic review is that we
used multiple scientific publication databases to identify
articles in our efforts to comprehensively assess the effects of
health insurance coverage disruptions on care and cancer outcomes. We included many years of published studies in our
search, starting in 1980. We also hand-searched the reference
lists of each included article for any additional published studies that were not initially captured in the electronic search process. It is possible we missed some relevant studies, however.
In addition, although we used standardized data abstraction
measures, there still may be some unavoidable subjectivity in
some of the measures we abstracted and reported. Finally, because of the heterogeneity of measures, study populations, and
cancer sites, we could not conduct quantitative meta-analyses.
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